INTRODUCTION {#s1}
============

Lung cancer, the leading cause of cancer-related death in most countries, has been increasing rapidly in China for the last three decades \[[@R1]\]. The risk of lung cancer is strongly associated with exposure to environmental carcinogens, in particular to cigarette smoke \[[@R2]\]. However, only approximately 10% of smokers ever develop lung cancer. This highlights the potential role of hereditary components in determining the risk of lung cancer \[[@R3]\]. Through genome-wide association studies (GWAS), a number of genes involved in lung carcinogenesis have been identified in populations of European descent. These include *CHRNA5*, *CHRNA3* and *CHRNA4* on chromosome 15q25.1 \[[@R4]--[@R6]\], (*TERT-CLPTM1L*) on 5p15.33 \[[@R7], [@R8]\], and (*BAT3-MSH5*) on 6p21.33 \[[@R7]\].

It was also learned from GWAS that inherited single nucleotide polymorphisms (SNPs) in telomere-related genes are associated with various malignancies \[[@R9]\]. Human telomeres, composed of a tandem hexanucleotide repeat (TTAGGG), are many kilobases long in newborns but shorten by an average of 20-40 base-pairs annually \[[@R10]\]. SNPs in the telomere-related gene *ACYP2* are reproducibly associated with inter-individual variation in leukocyte telomere length (LTL) \[[@R11]\]. In addition, recent Mendelian randomization studies indicate that LTL-associated SNPs related to longer telomere lengths are associated with increased risk of adult glioma, melanoma and lung cancer \[[@R12]\].

As far as we know, no studies have investigated the correlations between SNPs in *ACYP2* and lung cancer susceptibility. We therefore performed a case-control association study to determine whether any of 13 SNPs in the *ACYP2* gene are associated with lung cancer susceptibility in the Chinese Han population.

RESULTS {#s2}
=======

Participant characteristics {#s2_1}
---------------------------

A total of 554 lung cancer patients (416 males, 138 females; median age at diagnosis 48.24 ± 13.05 years) and 603 healthy subjects (469 males, 134 females; median age 58.18 ± 10.53 years) were enrolled in our study. There is significant difference in age between patients in the case and control groups (*p*\<0.001), but no difference in gender (Table [1](#T1){ref-type="table"}).

###### Characteristics of the cases and controls

  Variables         Case (N=554)    Control (N=603)   Total   *p*
  ----------------- --------------- ----------------- ------- ------------
  Gender, No. (%)                                             0.282^a^
   Male             416 (75.1%)     469 (77.8%)       885     
   Female           138 (24.9%)     134 (22.2%)       272     
  Mean age ±SD      48.24 ± 13.05   58.18 ± 10.53             \<0.001^b^

^a^ *p* was calculated using the chi-square test.

*^b^ p* was calculated using Student\'s t-test.

Association between *ACYP2* polymorphisms and lung cancer risk {#s2_2}
--------------------------------------------------------------

The minor allele of each SNP was assumed to be a risk factor. The minor allele frequencies (MAF) are listed in Table [2](#T2){ref-type="table"}. As a risk factor, the minor allele of each SNP was compared with the wild-type allele. All of the tested SNPs were consistent with the Hardy-Weinberg equilibrium for the control population of this study (*p*\>0.05). Comparing the differences in the frequency distributions of the alleles between the cases and controls using the χ^2^ test, we found no correlation between the loci and lung cancer susceptibility.

###### Basic information on the candidate SNPs

  Rs number    Nucleotide position   Allele A/B   MAF frequency   HW *p*   Allele model   *p*                   
  ------------ --------------------- ------------ --------------- -------- -------------- ------- ------------- -------
  rs6713088    54345469              G/C          0.404           0.393    0.089          1.048   0.887-1.237   0.585
  rs12621038   54391113              T/C          0.454           0.465    0.368          0.956   0.812-1.126   0.591
  rs1682111    54427979              A/T          0.347           0.309    0.924          1.189   1.000-1.415   0.051
  rs843752     54446587              G/T          0.234           0.260    0.089          0.870   0.720-1.052   0.151
  rs10439478   54459450              C/A          0.430           0.433    0.245          0.987   0.837-1.164   0.880
  rs843645     54474664              G/T          0.225           0.250    0.065          0.874   0.721-1.059   0.169
  rs11125529   54475866              A/C          0.195           0.187    0.503          1.054   0.857-1.298   0.617
  rs12615793   54475914              A/G          0.211           0.200    0.702          1.072   0.876-1.312   0.499
  rs843711     54479117              T/C          0.436           0.448    0.510          0.953   0.809-1.123   0.567
  rs11896604   54479199              G/C          0.214           0.200    0.800          1.087   0.889-1.330   0.415
  rs843706     54480369              A/C          0.432           0.452    0.459          0.925   0.784-1.091   0.355
  rs17045754   54496757              C/G          0.196           0.187    1.000          1.062   0.863-1.307   0.570
  rs843720     54510660              G/T          0.380           0.343    0.527          1.171   0.988-1.388   0.068

SNPs: Single nucleotide polymorphisms; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium; OR: Odds ratio; CI: Confidence interval; A: Minor alleles; B: Major alleles.

After adjusting for age, the models were further analyzed using unconditional logistic regression analysis of SNPs associated with lung cancer (Table [3](#T3){ref-type="table"}). We found that the AA genotype of rs1682111 was associated with increased lung cancer risk under the recessive model (crude, OR=1.50, 95%CI: 1.04-2.16, *p*=0.029; adjusted for age, OR=1.55, 95%CI: 1.04-2.30, *p*=0.029). We also noticed that rs11896604 was associated with lung cancer risk in codominant model ("GG", crude, OR=0.65, 95%CI: 0.33-1.28, *p*=0.045; adjusted for age, OR=0.74, 95%CI: 0.36-1.53, *p*=0.049) and over-dominant model ("CG", crude, OR=1.30, 95%CI: 1.02-1.66, *p*=0.032; adjusted for age, OR=1.37, 95%CI: 1.05-1.78, *p*=0.020). In addition, the GG genotype of rs843720 increased the risk of lung cancer under the recessive model (crude, OR=1.43, 95%CI: 1.02-2.02, *p*=0.040; adjusted for age, OR=1.48, 95%CI: 1.02-2.15, p=0.040).

###### Single loci associated with lung cancer (adjusted by age)

  snps         Model           Genotype   Controls(n%)   Cases(n%)     Without adjustment   With adjustment                      
  ------------ --------------- ---------- -------------- ------------- -------------------- ----------------- ------------------ -------
  rs1682111    Codominant      T/T        287 (47.6%)    244 (44.0%)   1\[Ref\]                               1\[Ref\]           
                               T/A        259 (43%)      235 (42.4%)   1.07 (0.83-1.36)                       1.01 (0.78-1.32)   
                               A/A        57 (9.4%)      75 (13.5%)    1.55 (1.05-2.27)     0.080             1.56 (1.03-2.37)   0.092
               Dominant        T/T        287 (47.6%)    244 (44.0%)   1\[Ref\]                               1\[Ref\]           
                               T/A-A/A    316 (52.4%)    310 (56.0%)   1.15 (0.9-21.45)     0.230             1.11 (0.86-1.43)   0.420
               Recessive       T/T-T/A    546 (90.5%)    479 (86.5%)   1\[Ref\]                               1\[Ref\]           
                               A/A        57 (9.4%)      75 (13.5%)    1.50 (1.04-2.16)     0.029             1.55 (1.04-2.30)   0.029
               Over-dominant   T/T-A/A    344 (57%)      319 (57.6%)   1\[Ref\]                               1\[Ref\]           
                               T/A        259 (43%)      235 (42.4%)   0.98 (0.77-1.24)     0.850             0.93 (0.72-1.19)   0.550
               Log-additive    ---        ---            ---           1.18 (1.00-1.40)     0.054             1.17 (0.97-1.41)   0.100
  rs11896604   Codominant      C/C        386 (64.1%)    331 (59.8%)   1\[Ref\]                               1\[Ref\]           
                               C/G        191 (31.7%)    209 (37.7%)   1.28 (1.00-1.63)                       1.35 (1.03-1.76)   
                               G/G        25 (4.2%)      14 (2.50%)    0.65 (0.33-1.28)     0.045             0.74 (0.36-1.53)   0.049
               Dominant        C/C        386 (64.1%)    331 (59.8%)   1\[Ref\]                               1\[Ref\]           
                               C/G-G/G    216 (35.9%)    223 (40.2%)   1.20 (0.95-1.53)     0.130             1.28 (0.99-1.66)   0.062
               Recessive       C/C-C/G    577 (95.8%)    540 (97.5%)   1\[Ref\]                               1\[Ref\]           
                               G/G        25 (4.2%)      14 (2.50%)    0.60 (0.31-1.16)     0.120             0.66 (0.32-1.37)   0.260
               Over                                                                                                              
               dominant        C/C-G/G    411 (68.3%)    345 (62.3%)   1\[Ref\]                               1\[Ref\]           
                               C/G        191 (31.7%)    209 (37.7%)   1.30 (1.02-1.66)     0.032             1.37 (1.05-1.78)   0.020
               Log-additive    ---        ---            ---           1.09 (0.89-1.34)     0.400             1.16 (0.92-1.45)   0.200
  rs843720     Codominant      T/T        256 (42.5%)    217 (39.2%)   1\[Ref\]                               1\[Ref\]           
                               G/T        280 (46.4%)    252 (45.6%)   1.06 (0.83-1.36)                       1.07 (0.82-1.41)   
                               G/G        67 (11.1%)     84 (15.2%)    1.48 (1.02-2.14)     0.110             1.54 (1.03-2.29)   0.110
               Dominant        T/T        256 (42.5%)    217 (39.2%)   1\[Ref\]                               1\[Ref\]           
                               G/T-G/G    347 (57.5%)    336 (60.8%)   1.14 (0.90-1.44)     0.270             1.16 (0.90-1.50)   0.250
               Recessive       T/T-G/T    536 (88.9%)    469 (84.8%)   1\[Ref\]                               1\[Ref\]           
                               G/G        67 (11.1%)     84 (15.2%)    1.43 (1.02-2.02)     0.040             1.48 (1.02-2.15)   0.040
               Over                                                                                                              
               dominant        T/T-G/G    323 (53.6%)    301 (54.4%)   1\[Ref\]                               1\[Ref\]           
                               G/T        280 (46.4%)    252 (45.6%)   0.97 (0.77-1.22)     0.770             0.97 (0.75-1.25)   0.810
               Log-additive    ---        ---            ---           1.17 (0.99-1.39)     0.068             1.19 (0.99-1.43)   0.064

Finally, we also performed a Wald test using unconditional multivariate regression analysis to assess the associations between SNP haplotypes and lung cancer risk. However, no positive results were observed.

DISCUSSION {#s3}
==========

In this study, three SNPs (rs1682111, rs11896604 and rs843720) were found to be associated with the lung cancer susceptibility in the Chinese Han population. Rs1682111 was associated with increased lung cancer risk in the recessive model. An association between this locus and other diseases has not been previously reported. Although this is the first report that rs11896604 associates with lung cancer susceptibility in the codominant over-dominant model, it was previously suggested that rs11896604 associates with a decreased risk of breast cancer \[[@R13]\]. In addition, rs843720 associated with an increased the risk of lung cancer in the recessive model.

*ACYP2*, located on chromosome 2p16.2, encodes a small cytosolic enzyme acylphosphatase that catalyzes the dephosphorylation of phospho-enzyme intermediates of various membrane pumps, particularly the Ca^2+^/Mg^2+^-ATPase from sarcoplasmic reticulum of skeletal muscle \[[@R14]\]. The physiological function of *ACYP2* is not yet completely clear, however. Vos et al. reported that the rs1872328 variant of *ACYP2* was associated with cisplatin-induced ototoxicity in patients with osteosarcoma who did not receive potentially ototoxic cranial irradiation \[[@R15]\]. It was further suggested that severe oxaliplatin-induced chronic peripheral neurotoxicity was potentially associated with *ACYP2* rs843748 \[[@R16]\]. A recent genome-wide meta-analysis showed that *ACYP2* rs11125529 affects telomere length and coronary heart disease in the Chinese Han population \[[@R17]\]. In addition, Yongjun et al found that *ACYP2* rs12615793 and rs11896604 may significantly decrease the risk of high-altitude pulmonary edema \[[@R18]\]. However, the mechanism by which *ACYP2* contributes to lung cancer will need to be explored in future studies.

Although the present study has several strengths, it also has intrinsic limitations. First, we present no data on the relation between *ACYP2* SNPs and the most influential lung cancer risk: smoking. Second, the size of our sample is relatively small. Finally, other factors such as BMI, bacterial and viral infection, marriage, and economic status were not taken into account. Those issues will be addressed in future studies, along with further characterization of the molecular mechanism underlying the association of *ACYP2* SNPs and lung cancer and prospective studies to validate their clinical utility.

In sum, we have identified several novel associations between three SNPs in *ACYP2* (rs1682111, rs11896604 and rs843720) and lung cancer in the Chinese Han population. Our findings suggest *ACYP2* may be a useful marker that informs clinical decisions, and may shed light on new candidate genes and new ideas about the mechanism governing the occurrence of lung cancer.

MATERIALS AND METHODS {#s4}
=====================

Study participants {#s4_1}
------------------

We recruited 554 patients with lung cancer and 603 healthy controls for this study. The patients were treated at the First Affiliated Hospital of Xi'an Jiao Tong University between January 2014 and August 2016. All demographic and related clinical data, including residential region, age, ethnicity, and education status, were collected through a face-to-face questionnaire and review of medical records. Patients recently diagnosed with primary lung cancer (confirmed by histopathological analysis) were included. Patients with other types of cancers or who underwent radiotherapy or chemotherapy were excluded. The controls underwent annual health evaluations in the checkup centers affiliated with our institution. All control patients were in good health and had no history of cancer, and they had no blood relatives with lung cancer going back three generations. This research was performed in accordance with the Chinese Department of Health and Human Services regulations for the protection of human research subjects. We obtained informed consent from all of the participants, and the study protocols were approved by the Institutional Review Board of Xi'an Jiao Tong University.

SNP selection and genotyping {#s4_2}
----------------------------

Thirteen SNPs in *ACYP2* that had a MAF \>5% in the HapMap Asian population were selected for the association analysis \[[@R13], [@R14]\]. Venous blood samples (5 mL) were collected from each study participant during a laboratory examination. Blood samples from patients were collected prior to radiation or chemotherapy. DNA was extracted from whole blood samples using a Gold Mag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Ltd, Xian, China) and stored at --80°C after centrifugation. The DNA concentration was measured using spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). Sequenom MassARRAY Assay Design 3.0 software (Sequenom, Inc, San Diego, CA, USA) was used to design the multiplexed SNP Mass EXTEND assay, and genotyping was performed using a Sequenom MassARRAY RS1000 (Sequenom, Inc.) according to the manufacturer\'s protocol. SequenomTyper 4.0 Software™ (Sequenom, Inc.) was used to manage and analyze the data. The primers corresponding to each SNP are shown in Table [4](#T4){ref-type="table"}. Based on these results, the following 13 SNPs were selected: rs6713088, rs12621038, rs1682111, rs843752, rs10439478, rs843645, rs11125529, rs12615793, rs843711, rs11896604, rs843706, rs17045754 and rs843720. Basic information on the SNPs is shown in Table [2](#T2){ref-type="table"}.

###### Primers used

  SNP_ID       1st-PCRP                         2nd-PCRP                          UEP_SEQ
  ------------ -------------------------------- --------------------------------- ----------------------------
  rs6713088    ACGTTGGATGACACACACAGACTCCTTCAC   ACGTTGGATGGTCACCAAAACACGTAATG     gaggcCAGAATGGTCCACTAGAGA
  rs12621038   ACGTTGGATGATTGTGCTAGGCACTTTAGG   ACGTTGGATGGGCATAAGTTTTATTGCCTC    ccATTGCCTCAGCTAGACT
  rs1682111    ACGTTGGATGGAATTGCTGGGTTATTTGGC   ACGTTGGATGGCCAGTGGGAATGCAAAATG    tgtcATGCAAAATGAAACAGACACTT
  rs843752     ACGTTGGATGTCCTCTTTTCAGAAACCTGC   ACGTTGGATGGAGACAACATAATGGAGGTC    cGAGTTTGGGTTTGAGGT
  rs10439478   ACGTTGGATGTAGCACAAGACCTACACTGG   ACGTTGGATGCTACACTCTCCAGAGGAATG    TTGCTGTTTTCCCAGAA
  rs843645     ACGTTGGATGGAAATCTGAATACCACCTAC   ACGTTGGATGACAGTGCCTTTAGCAAGGTG    TCATAGGCACTACTGTATC
  rs11125529   ACGTTGGATGCCGAAGAAAAGAAGATGAC    ACGTTGGATGGAGCTTAGTTGTTTACAGATG   AGAAAAGAAGATGACTAAAACAT
  rs12615793   ACGTTGGATGATCTTGGCCCTTGAAGAA     ACGTTGGATGTTTGAGCTTAGTTGTTTAC     AAATTGAGTGACAAATATAAACTAC
  rs843711     ACGTTGGATGGACAAAGGACCTTACAACTC   ACGTTGGATGTGCCTTGTGGGAATTAGAGC    gggaTCAGGGAACCAGTGCAAA
  rs11896604   ACGTTGGATGAAGTCAGAATAGTGCTTAC    ACGTTGGATGTGTCTCTGACCTAGCATGTA    GTTAAGCTTGCAAGGAG
  rs843706     ACGTTGGATGTGAAAGCCATAAATATTTTG   ACGTTGGATGTGAATAACTTGGTCTTATC     cACTTGGTCTTATCTGATGC
  rs17045754   ACGTTGGATGCTGTAAAAGTTCTGGCATGG   ACGTTGGATGGAAATCAGGGATATTAGTGC    caggTATTCAGCTTCCTAGAGTTA
  rs843720     ACGTTGGATGCTTCACAACACTCCTGTAAG   ACGTTGGATGAGTCAGAGCTAGACCTCTGG    ccccAATCTGTCTCAGGGTCTT

Statistical analysis {#s4_3}
--------------------

We used Chi-squared tests (categorical variables) and Student\'s t-tests (continuous variables) to assess the differences in the demographic characteristics between the cases and controls. The Hardy-Weinberg equilibrium of each SNP was assessed in order to compare the expected frequencies of the genotypes in the control groups. All minor alleles were regarded as risk alleles for lung cancer susceptibility. To evaluate associations between each SNP and lung cancer risk in the five models (codominant, dominant, recessive, over-dominant and log-additive), ORs and 95% CIs were calculated using unconditional logistic regression analysis after adjusting for age, and gender. Linkage disequilibrium analysis and SNP haplotypes were analyzed using the Haploview software package (version 4.2) and the SHEsi software platform (<http://www.nhgg.org/analysis/>). All statistical analyses were performed using the SPSS version 17.0 statistical package (SPSS, Chicago, IL, USA) and Microsoft Excel. All statistical tests were two-sided, and values of *p*\<0.05 was considered significant.
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